Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis 18 (Mtb) and remains a major health problem worldwide. Thus, there is an urgent need to identify 19 new and more effective drugs to treat emerging multidrug-resistant TB (MDR-TB) and to 20 reduce the side effects of anti-TB drugs, such as liver toxicity and other detrimental changes. 21 In this study, to develop a novel candidate drug for effective TB treatment with few side effects 22 in the host, we selected pasakbumin A isolated from Eurycoma longifolia (E. longifolia) Jack, 23 which protected host cells against Mtb infection-induced death. Pasakbumin A significantly 24 inhibited intracellular Mtb growth by inducing autophagy via the ERK1/2-mediated signaling 25 pathway in Mtb-infected macrophages. We further investigated whether pasakbumin A could 26 be used as a potential adjuvant for TB treatment. Treatment with pasakbumin A and the anti-27 TB drug rifampicin (RMP) potently suppressed intracellular Mtb killing by promoting 28 autophagy as well as TNF-α production via the ERK1/2-and NF-κB-mediated signaling 29 pathways in Mtb-infected cells. Our results suggest that pasakbumin A could be developed as 30 a novel anti-TB drug or host-directed therapeutic (HDT) strategy to protect against host cell 31 death and improve host defense mechanisms against Mtb infection in macrophages.
Introduction 37
Tuberculosis (TB) is still one of the oldest known human diseases and a major cause of 38 mortality among the infectious diseases [1] . Mycobacterium tuberculosis (Mtb), the causative 7 116 macrophages ( Fig. 1D) . These results suggest that pasakbumin A controls intracellular Mtb 117 growth by enhancing NO and TNF-α production by macrophages and protects against host cell 118 death during Mtb infection. Mtb alone ( Fig. 2A) . Our previous study demonstrated that lysophosphatidylcholine (LPC) 128 controls intracellular Mtb survival by promoting phagosomal maturation in Mtb-infected cells, 129 based on elevated levels of cleaved cathepsin D[29], a lysosomal aspartic protease that 130 undergoes several proteolytic processing events to produce a mature protein at an acidic pH.
131
To investigate whether pasakbumin A can control phagosomal maturation in Mtb-infected cells, 132 we also detected the expression level of cleaved cathepsin D in Mtb-infected cells. As shown 133 in Fig. 2A H37Rv-infected Raw264.7 cells (Fig. 2B) . These data demonstrated that pasakbumin A We used the pharmacologic inhibitor U0126 to inhibit the ability of MEK1/2 to activate 159 ERK1/2. As shown Fig. 3A , inhibition of ERK1/2 entirely failed to suppress intracellular Mtb 160 growth in the presence or absence of pasakbumin A during H37Rv infection. In addition, 9 161 treatment with the ERK1/2 inhibitor decreased NO and TNF-α production, whereas it slightly 162 increased IL-10 production in pasakbumin A-treated Raw264.7 cells during H37Rv infection, 163 similar to the effect observed in cells infected with H37Rv alone (Fig. 3B-3D) . These results 164 indicated that ERK1/2-mediated signaling could control intracellular Mtb growth and to 165 produce inflammatory mediators in pasakbumin A-treated macrophages. infected with H37Rv without pasakbumin A (Fig. 4B) . However, the number of endogenous 180 LC3-positive puncta was significantly reduced by the ERK1/2 inhibitor U0126 in pasakbumin 181 A-treated Raw264.7 cells during H37Rv infection, similar to those infected with H37Rv alone 182 ( Fig. 4B) . These results indicated that ERK1/2-mediated signaling was important not only for 183 autophagy induction but also for the production of inflammatory mediators after pasakbumin ). In addition, TNF-α secretion was irregularly increased by RMP in a dose-dependent 201 manner; however, more was produced in Mtb-infected cells treated with pasakbumin A and 202 RMP than Mtb-infected cells treated with RMP alone (Fig. 5B) . In contrast, combined 203 treatment of pasakbumin A and RMP showed stronger decreases in IL-10 secretion than that 204 of cells treated with pasakbumin A in the absence of RMP during Mtb infection (Fig. 5C) . 205 There was no significant difference in NO production after RMP treatment in pasakbumin A-11 206 treated cells (Fig. 5D) . These data suggested that the combination of pasakbumin A with an 207 anti-TB drug effectively suppressed intracellular Mtb growth by promoting the production of 208 pro-inflammatory cytokine and blocking the production of anti-inflammatory cytokine in 209 macrophages. with those treated with pasakbumin A alone (Fig. 6A) . We also found that combined treatment 220 of pasakbumin A and RMP strongly induced the conversion of LC3-I to LC3-II in Mtb-infected 221 cells (Fig. 6A) . To further confirm this observation, we detected endogenous LC3 by 222 immunofluorescence staining. After combined treatment of pasakbumin A and RMP, the 223 percentage of FITC-LC3-positive cells with punctate staining was greater than that of Mtb-224 infected cells treated with pasakbumin A alone (Fig. 6B) . These data suggest that pasakbumin 
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The multidrug regimen of anti-TB drugs has also been associated with an increased 237 incidence of adverse effects that cause mild to severe host damage; these effects may cause 238 discontinuation of the treatment due to the poor health and immunity of TB patients [20] . 
Materials and Methods

295
Cell culture 296 The mouse macrophage cell line, Raw264.7, was purchased from ATCC (ATCC, Rockville, 297 MD, USA). Cells were maintained in RPMI-1640 (Cellgro, Herndon, VA, USA) supplemented 298 with 10% fetal bovine serum (FBS, Atlas Biologicals, Fort Collins, CO) and 1% 299 penicillin/streptomycin (Corning Incorporated, Corning, NY, USA). Cells were cultured in a 300 standard cell culture incubator at 37 °C with an atmosphere of 5% CO 2 and 95% air. 
